Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India)

Full text
Author(s):
Sanches, Paulo R. S. [1] ; Charlie-Silva, Ives [2] ; Braz, Helyson L. B. [3] ; Bittar, Cintia [4] ; Calmon, Marilia Freitas [4] ; Rahal, Paula [4] ; Cilli, Eduardo M. [1]
Total Authors: 7
Affiliation:
[1] Sao Paulo State Univ, Inst Chem, UNESP, Araraquara, SP - Brazil
[2] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Sao Paulo, SP - Brazil
[3] Univ Fed Ceara, Dept Morphol, Sch Med, Fortaleza, Ceara - Brazil
[4] Sao Paulo State Univ, Inst Biosci Language & Exact Sci, UNESP, Sao Jose Do Rio Preto, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: JOURNAL OF VIRUS ERADICATION; v. 7, n. 3 SEP 2021.
Web of Science Citations: 0
Abstract

New variants of SARS-CoV-2 Alpha (B.1.1.7); Beta (B.1.351) Gamma (P.1) and Delta (B.1.617.2) quickly spread in the UK, South Africa, Brazil and India, respectively. To address whether mutations in SARS-CoV-2 RBD spike protein could affect virus infectivity, peptides containing RBD amino acids mutations have been constructed and interacted with human ACE2 by computational methods. Our results suggest that mutations in RBD amino acids K417, E484, L452, T478 and N501 are expressively increasing the affinity of this protein with human angiotensin-converting enzyme 2 (ACE2), consequently, variants Alpha (B.1.1.7), Beta (B1.351), Gamma (P.1) and Delta (B.1.617.2) could be more infective in human cells compared with SARS-CoV-2 isolated in Wuhan2019 and the Gamma and Delta variants could be the most infective among them. (AU)

FAPESP's process: 20/12519-4 - Study of the action of synthetic peptides as antivirals against SARS-CoV-2 (COVID-19) and combined evaluation with commercial anti-inflammatories
Grantee:Paulo Ricardo da Silva Sanches
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 20/05761-3 - Study of the action of synthetic peptides as antivirals against SARS-CoV-2 (COVID-19) and combined evaluation with commercial anti-inflammatories
Grantee:Eduardo Maffud Cilli
Support type: Regular Research Grants